Show simple item record

dc.contributor.authorJackisch, C.
dc.contributor.authorCortazar, P.
dc.contributor.authorGeyer, C. E.
dc.contributor.authorGianni, L.
dc.contributor.authorGligorov, J.
dc.contributor.authorMachackova, Z.
dc.contributor.authorPerez, E. A.
dc.contributor.authorSchneeweiss, A.
dc.contributor.authorTolaney, S. M.
dc.contributor.authorUntch, M.
dc.contributor.authorWardley, Andrew M
dc.contributor.authorPiccart, M.
dc.date.accessioned2021-09-30T11:56:16Z
dc.date.available2021-09-30T11:56:16Z
dc.date.issued2021en
dc.identifier.citationJackisch C, Cortazar P, Geyer CE Jr, Gianni L, Gligorov J, Machackova Z, et al. Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. Cancer Treatment Reviews. 2021 Sep;99:102229.en
dc.identifier.pmid34139476en
dc.identifier.doi10.1016/j.ctrv.2021.102229en
dc.identifier.urihttp://hdl.handle.net/10541/624654
dc.description.abstractTreatment of HER2-positive early breast cancer (EBC) continues to evolve with neoadjuvant (pre-operative) and adjuvant (post-operative) HER2-targeted therapies as standard of care. There are two important decision points. The first involves deciding between neoadjuvant therapy or proceeding directly to surgery. Neoadjuvant chemotherapy (NACT) plus pertuzumab-trastuzumab is appropriate for patients with high-risk HER2-positive EBC (tumour diameter ≥2 cm, and/or node-positive disease). Patients with node-negative disease and tumour diameter <2 cm are candidates for upfront surgery followed by paclitaxel for 12 weeks plus 18 cycles of trastuzumab, with the option to add pertuzumab (if pN+). The second decision point involves the pathohistological result at surgery after neoadjuvant therapy. Total pathological complete response (tpCR: ypT0/is, ypN0) is associated with improved survival endpoints. Patients with tumours ≥2 cm and/or node-positive disease at diagnosis who have a tpCR after dual blockade should continue pertuzumab-trastuzumab in the adjuvant setting to complete 1 year (18cycles) of treatment. For patients with invasive residual disease, 14cycles of post-neoadjuvant trastuzumab emtansine (T-DM1) therapy significantly increases invasive-DFS compared with trastuzumab. Extended adjuvant therapy with neratinib is an option in selected patients (HER2-positive and oestrogen receptor [ER]-positive) who have completed adjuvant trastuzumab-based therapy. Less aggressive chemotherapy regimens are recommended in populations with a lower risk of recurrence (patients with small tumours without axillary involvement; patients unlikely to tolerate anthracycline-taxane or taxane-carboplatin regimens). Ultimately, treatment recommendations should be consistent with local and international guidelines. Further studies will guide optimisation of treatment for patients with HER2-positive EBC according to the risk of disease recurrence.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ctrv.2021.102229en
dc.titleRisk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledgeen
dc.typeArticleen
dc.contributor.departmentAGO-B and Sana Klinikum Offenbach GmbH, Offenbach, Germanyen
dc.identifier.journalCancer Treatment Reviewsen
dc.description.noteen]
refterms.dateFOA2021-10-13T09:06:08Z


Files in this item

Thumbnail
Name:
34139476.pdf
Size:
1.108Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record